Outlook Therapeutics, Inc.
Developing an ophthalmic bevacizumab to treat retinal diseases like wet AMD.
OTLK | US
Overview
Corporate Details
- ISIN(s):
- US69012T3059 (+1 more)
- LEI:
- Country:
- United States of America
- Address:
- 111 S. WOOD AVENUE, 8830 ISELIN
- Website:
- https://outlooktherapeutics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010 / LYTENAVA™ (bevacizumab-vikg), an ophthalmic formulation of bevacizumab for the treatment of retinal diseases. The company's primary focus is on conditions such as wet age-related macular degeneration (wet AMD). Its key product, LYTENAVA™, is the first ophthalmic formulation of bevacizumab to receive Marketing Authorization from the European Commission and the UK's MHRA for wet AMD, with a commercial launch planned for the EU and UK. In the United States, ONS-5010 is an investigational drug with a Biologics License Application resubmitted to the FDA. If approved, it would be the first FDA-approved ophthalmic bevacizumab for retinal indications.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Outlook Therapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Outlook Therapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Outlook Therapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
